A HTG é comumente encontrada na prática clínica.[5]Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. Eur Heart J. 2020 Jan 1;41(1):99-109c.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938588
http://www.ncbi.nlm.nih.gov/pubmed/31764986?tool=bestpractice.com
[13]Simha V. Management of hypertriglyceridemia. BMJ. 2020 Oct 12;371:m3109.
http://www.ncbi.nlm.nih.gov/pubmed/33046451?tool=bestpractice.com
Dependendo da definição, a prevalência global varia de 10% a 25% na população adulta com considerável variação entre regiões.[5]Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. Eur Heart J. 2020 Jan 1;41(1):99-109c.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938588
http://www.ncbi.nlm.nih.gov/pubmed/31764986?tool=bestpractice.com
[13]Simha V. Management of hypertriglyceridemia. BMJ. 2020 Oct 12;371:m3109.
http://www.ncbi.nlm.nih.gov/pubmed/33046451?tool=bestpractice.com
[15]Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the national health and nutrition examination survey 2003-2006. J Clin Lipidol. 2012 Jul-Aug;6(4):325-30.
http://www.ncbi.nlm.nih.gov/pubmed/22836069?tool=bestpractice.com
[16]Toth PP, Fazio S, Wong ND, et al. Risk of cardiovascular events in patients with hypertriglyceridaemia: a review of real-world evidence. Diabetes Obes Metab. 2020 Mar;22(3):279-89.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065050
http://www.ncbi.nlm.nih.gov/pubmed/31742844?tool=bestpractice.com
[17]Martin SS, Aday AW, Almarzooq ZI, et al. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024 Feb 20;149(8):e347-913.
https://www.ahajournals.org/doi/10.1161/CIR.0000000000001209
http://www.ncbi.nlm.nih.gov/pubmed/38264914?tool=bestpractice.com
A prevalência de HTG leve a moderada tem aumentado nas últimas décadas em paralelo com a obesidade, resistência à insulina e diabetes do tipo 2.[5]Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. Eur Heart J. 2020 Jan 1;41(1):99-109c.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938588
http://www.ncbi.nlm.nih.gov/pubmed/31764986?tool=bestpractice.com
[18]Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011 May 24;123(20):2292-333.
https://www.ahajournals.org/doi/10.1161/CIR.0b013e3182160726
http://www.ncbi.nlm.nih.gov/pubmed/21502576?tool=bestpractice.com
A prevalência de HTG grave, definida como concentração plasmática de triglicerídeos >10 mmol/L (>885 mg/dL), varia de 0.10% a 0.20%, e a prevalência de HTG muito grave, definida como triglicerídeos >20 mmol/L ( >1770 mg/dL), varia de 0.010% a 0.020%.[5]Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. Eur Heart J. 2020 Jan 1;41(1):99-109c.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938588
http://www.ncbi.nlm.nih.gov/pubmed/31764986?tool=bestpractice.com